Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India.
Amity Institute of Biotechnology, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India,
Front Biosci (Landmark Ed). 2020 Mar 1;25(8):1462-1487. doi: 10.2741/4864.
Human kinases represent a large family of enzymes with their primary function being the phosphorylation of various biomolecules. Kinases along with G-Protein Coupled Receptors (GPCRs) represent wo of the most common protein targest in drug discovery. Kinases are classified by the substrate they phosphorylate namely, protein kinases, carbohydrate kinases and lipid kinases. These different classes have unique mechanism of action but show considerable overlap in their structural assembly and sequence of chemical modifications. Compounds can modulate kinadse activity by interacting with the enzyme's ATP binding site (orthostatic site) or the allosteric site. These modulators have been classified as Types I, II, III and IV depending on their mode of binding. Inclusion of atypical kinases and pseuokinases in the targetable kinome along with the recent approval of kinase-based therapeutics provides an impetus to the ever-growing field of kinase modulation. This review attempts to summarize the identification, historical stance, catalytic structure and subsequent development of kinases as significvant drug targets with an emphasis on their catalytic machinery and modulation.
人类激酶是一大类酶,其主要功能是磷酸化各种生物分子。激酶与 G 蛋白偶联受体 (GPCR) 一起,是药物发现中最常见的两种蛋白质靶点。激酶根据其磷酸化的底物进行分类,即蛋白激酶、糖激酶和脂激酶。这些不同的类别具有独特的作用机制,但在结构组装和化学修饰顺序上有很大的重叠。化合物可以通过与酶的 ATP 结合位点(变构位点)或别构位点相互作用来调节激酶活性。这些调节剂根据其结合模式被分类为 I 型、II 型、III 型和 IV 型。靶向激酶组中的非典型激酶和伪激酶的纳入,以及基于激酶的治疗方法的最近批准,为激酶调节这一日益增长的领域提供了动力。本综述试图总结激酶作为重要药物靶点的鉴定、历史地位、催化结构和随后的发展,重点是其催化机制和调节。